FDA Clearance Tracker · K230248
VIOLA
Last checked: Nov 19, 2026Latest source record: Feb 28, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Feb 28, 2023
Substantially Equivalent
Time to decision
29 days
Received Jan 30, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K230248
- Device name
- VIOLA
- Applicant
- Vascular Graft Solutions, Ltd.
- Applicant location
- Tel Aviv, IL
- Received
- Jan 30, 2023
- Decided
- Feb 28, 2023
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Clamp, Vascular (DXC)
- Device class
- Class II
- Regulation
- 21 CFR 870.4450
- Specialty
- Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DXC. The earliest in FDA's data is K761169, decided Dec 9, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K230248
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Vascular Graft Solutions, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VIOLA510(k)
K203307 · Decided Feb 17, 2021 · 100 days after receipt
Device type: Clamp, Vascular (DXC) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.